Evidence map›Paper›PMID 39268577›Full record

ArticleNucleic acids research2024

RTP801 interacts with the tRNA ligase complex and dysregulates its RNA ligase activity in Alzheimer's disease.

Genís Campoy-Campos, Julia Solana-Balaguer, Anna Guisado-Corcoll, Almudena Chicote-González, Pol Garcia-Segura, Leticia Pérez-Sisqués, Adrian Gabriel Torres, Mercè Canal, Laura Molina-Porcel, Joaquín Fernández-Irigoyen and 7 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Genís Campoy-CamposDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Julia Solana-BalaguerDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Anna Guisado-CorcollDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Almudena Chicote-GonzálezDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Pol Garcia-SeguraDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Leticia Pérez-SisquésDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Adrian Gabriel TorresInstitut de Recerca Biomèdica (IRB Barcelona), Barcelona 08028, Catalonia, Spain.
Mercè CanalDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Laura Molina-PorcelAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), University of Barcelona, Barcelona 08036, Catalonia, Spain.
Joaquín Fernández-IrigoyenProteored-ISCIII, Proteomics Unit, Navarrabiomed, Departamento de Salud, UPNA, IdiSNA, Pamplona 31008, Spain.
Enrique SantamariaProteored-ISCIII, Proteomics Unit, Navarrabiomed, Departamento de Salud, UPNA, IdiSNA, Pamplona 31008, Spain.
Lluís Ribas de PouplanaInstitut de Recerca Biomèdica (IRB Barcelona), Barcelona 08028, Catalonia, Spain.ORCID 0000-0002-2087-0359
Jordi AlberchDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Eulàlia MartíDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Albert GiraltDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Esther Pérez-NavarroDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Cristina MalageladaDepartament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.ORCID 0000-0001-7185-436X

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca #FI-B-00378Agencia Estatal de Investigación SAF2017-88812-RCIBERNEDERDF A way of making Europe PID2020-119386RB-I00European Union NextGenerationEU/PRTR CNS2022 - 135391Fundación Ramón Areces CIVP21A7024Generalitat de Catalunya 2021 SGR 01086Michael J. Fox Foundation MJFF-000858Ministry of Science, Innovation, and UniversitiesSpanish Ministry of Science and Innovation #FPU18/00194Universitat de BarcelonaUniversity of Barcelona MDM-2017-0729
6 · The paper itself

Abstract

RTP801/REDD1 is a stress-responsive protein overexpressed in neurodegenerative diseases such as Alzheimer's disease (AD) that contributes to cognitive deficits and neuroinflammation. Here, we found that RTP801 interacts with HSPC117, DDX1 and CGI-99, three members of the tRNA ligase complex (tRNA-LC), which ligates the excised exons of intron-containing tRNAs and the mRNA exons of the transcription factor XBP1 during the unfolded protein response (UPR). We also found that RTP801 modulates the mRNA ligase activity of the complex in vitro since RTP801 knockdown promoted XBP1 splicing and the expression of its transcriptional target, SEC24D. Conversely, RTP801 overexpression inhibited the splicing of XBP1. Similarly, in human AD postmortem hippocampal samples, where RTP801 is upregulated, we found that XBP1 splicing was dramatically decreased. In the 5xFAD mouse model of AD, silencing RTP801 expression in hippocampal neurons promoted Xbp1 splicing and prevented the accumulation of intron-containing pre-tRNAs. Finally, the tRNA-enriched fraction obtained from 5xFAD mice promoted abnormal dendritic arborization in cultured hippocampal neurons, and RTP801 silencing in the source neurons prevented this phenotype. Altogether, these results show that elevated RTP801 impairs RNA processing in vitro and in vivo in the context of AD and suggest that RTP801 inhibition could be a promising therapeutic approach.

Indexed as

Alzheimer DiseaseHippocampusTranscription FactorsX-Box Binding Protein 1AnimalsDEAD-box RNA HelicasesDisease Models, AnimalHEK293 CellsHumansMaleMiceNeuronsRNA Ligase (ATP)RNA SplicingRNA, TransferUnfolded Protein ResponseDDIT4 protein, humanDEAD-box RNA HelicasesRNA Ligase (ATP)RNA, TransferTranscription FactorsX-Box Binding Protein 1XBP1 protein, human

Identifiers

PMID39268577
PMCPMC11472047

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.